ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i [j] k l m n o p q r s t u v w x y z

Abstract Number: 0195

JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Abstract Number: 0029

JAK1 Regulates Autophagy and Reinforces the Inflammatory and Autoimmune Potentials in Rheumatoid Arthritis Synovial Fibroblasts
Abstract Number: 0773

Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
Abstract Number: 0259

JIA Diagnoses and Trends from 2006-2019: Has the U.S. ICD-9-to-ICD-10 Transition Created Coding Artifacts?
Abstract Number: 0008

Jo-1-Binding and Clonally-Expanded Memory B Cells Express Germline and Somatically-Mutated B Cell Receptors in Anti-tRNA Synthetase Syndrome Patients
Abstract Number: 0264

Joint Acoustic Emissions as a Biomarker to Differentiate Between Active and Inactive Juvenile Idiopathic Arthritis via 2-stage Machine Learning Classifier
Abstract Number: 1510

Joint CD8+ Tissue Resident Memory Cell Activation Produces Local Inflammatory Arthritis
Abstract Number: 0726

Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Abstract Number: 1018

Joint-Draining Popliteal Lymphatic Vessels Exhibit Lymphatic Muscle Cell Dysfunction in TNF-Tg Mice with Inflammatory Arthritis
Abstract Number: 1349

Joint-specific Responses to Tofacitinib and Adalimumab in Patients with Psoriatic Arthritis: Post Hoc Analysis of a Phase 3 Study

Jump to: View All • a b c d e f g h i [j] k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].